Equillium, Inc. Common Stock (EQ)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 14
- Market Cap
- $122M
About Equillium, Inc. Common Stock
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
SentiSense also tracks daily options readings for Equillium, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Equillium, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.